Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a research note issued to investors on Saturday.

Other analysts also recently issued reports about the company. UBS Group upped their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Finally, Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Four analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $791.05.

Regeneron Pharmaceuticals Stock Down 3.6%

Shares of NASDAQ REGN opened at $768.00 on Friday. The firm’s 50-day moving average is $740.64 and its two-hundred day moving average is $631.30. The company has a market capitalization of $80.72 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 2.16 and a beta of 0.39. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period last year, the company posted $12.46 EPS. The company’s revenue was up .9% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. PGGM Investments increased its stake in Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after purchasing an additional 51,900 shares in the last quarter. Founders Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after buying an additional 538 shares during the period. Generate Investment Management Ltd purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $6,300,000. Osaic Holdings Inc. increased its position in shares of Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after acquiring an additional 6,073 shares in the last quarter. Finally, Hudson Value Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $398,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.